The aim of the present study was to quantitate the hypoglycaemic effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagonlike peptide-1 receptor agonists (GLP-1r) and sodium glucose cotransporter 2 inhibitors (SGLT2i) as add-on treatments to metformin monotherapy in patients with type 2 diabetes mellitus (T2DM) using a model-based meta-analysis (MBMA).
Introduction
Type 2 diabetes mellitus (T2DM) is characterized by a chronic hyperglycaemic state due to decreases in insulin secretion and sensitivity [1, 2] . The estimated prevalence of diabetes worldwide is more than 400 million, and the total number of patients with diabetes is predicted to increase to 629 million by 2045 [3] . Appropriate glycaemic control based on haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) is required in order to prevent various complications, such as retinopathy, nephropathy, and neuropathy [4, 5] . The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend metformin as first-line monotherapy for most T2DM patients [6] . Metformin is a biguanide that decreases blood glucose concentrations by inhibiting gluconeogenesis in the liver [7] . Secondary failure may occur after long-term metformin therapy [8] [9] [10] [11] . Therefore, the ADA and EASD recommend dual therapy with metformin and other antidiabetic drugs if glycaemic control is not achieved. There is an extensive list of pharmacological therapies available for the second-line adjunctive treatment of T2DM, including sulfonylureas (SU), thiazolidines (TZD), dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1r), sodium glucose cotransporter 2 inhibitors (SGLT2i), and basal insulins. DPP-4i, GLP-1r and SGLT2i, which have novel mechanisms of action, are less likely to cause weight gain and hypoglycaemia [12] [13] [14] ; therefore, the use of these drugs is increasing. In Japan, the share of DPP-4i in the total oral antidiabetic drugs market reached 69% in 2015 [15] . In terms of dual therapy with metformin monotherapy, since few randomized controlled trials (RCTs) have directly compared the efficacy of these drugs, a consistent consensus regarding the most appropriate drugs as add-ons is lacking.
A model-based meta-analysis (MBMA) is an extension of a traditional meta-analysis. A traditional meta-analysis has the following limitations: (1) it may only be applicable when direct head-to-head RCTs exist, and (2) observation periods and doses are limited to specific ranges. In contrast, MBMA, which involves a meta-analysis using mathematical models, has the capacity to perform indirect comparisons even though head-to-head RCTs are lacking. In addition, MBMA may incorporate longitudinal and dose-response data, thereby allowing for the quantification of dose-response relationships and time courses of effects. Therefore, MBMA is more flexible than a traditional meta-analysis and is expected to provide more information [16, 17] .
The aim of the present study was to develop a population pharmacodynamic (PPD) model that quantitates the FPGand HbA1c-lowering effects of DPP-4i, GLP-1r and SGLT2i as add-ons to metformin monotherapy in T2DM patients using an MBMA approach.
Methods

Literature search
The 'targeted drugs' in the present study included DPP-4i (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin, saxagliptin, trelagliptin and omarigliptin), GLP-1r (liraglutide, exenatide, lixisenatide and dulaglutide), and SGLT2i (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, canagliflozin and empagliflozin), which are all approved in Japan. A systematic literature search of PubMed, the Cochrane library (CENTRAL/CCTR: Cochrane Central Register of Controlled Trials), and ClinicalTrials.gov (https:// clinicaltrials.gov/) was conducted on 3 March 2016. The words used in the search were ('metformin' OR 'targeted drugs') AND ('diabetes' OR 'diabetic'). Details of the search terms are provided in Supplementary Table S1 . Only clinical trials satisfying the following inclusion criteria were included in the analysis: (1) randomized double-blind clinical trials, (2) patients diagnosed with T2DM, (3) targeted drugs added to metformin monotherapy because of inadequate glycaemic control, (4) HbA1c or FPG values used as clinical indicators, and (5) published in English. We excluded trials focusing on specific populations, such as renal failure and paediatric subjects. MBMA was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [18] .
We extracted the following information from eligible studies: mean and median values of HbA1c and FPG at each time point, sample size, dosage, duration of T2DM, duration of metformin therapy, age, sex, race (e.g., Caucasians, Asians, and others), body mass index (BMI) and body weight. Graphical data were converted to numerical data using GetData Graph Digitizer ® version 2.26 (http://getdata-graphdigitizer.com).
Model development
A PPD analysis was performed using NONMEM 7.3.0 (Icon Development Solutions, Ellicott City, Maryland) with firstorder conditional estimation with interaction method (FOCE-INTER). Graphical processing of the NONMEM output was performed with R (version 3.3.2). In the present study, a physiological indirect response model was established to describe the time courses of FPG and HbA1c [19] . Overall model structures for FPG and HbA1c are shown as follows:
where K in,FPG and K out,FPG are the FPG production rate constant and FPG elimination rate constant, respectively. Changes in HbA1c were modelled as secondary changes dependent on the baseline ratio of FPG (FPG/Baseline FPG ), with the HbA1c production rate constant (K in,HbA1c ) and HbA1c elimination rate constant (K out,HbA1c ). The description of HbA1c production also included the use of the power function λ [20] [21] [22] . K in,HbA1c is defined by K in,HbA1c = Baseline HbA1c × K out,HbA1c . Baseline FPG and Baseline HbA1c represent FPG and HbA1c levels before the initiation of dual therapies, respectively. Baseline FPG and Baseline HbA1c in the x th biomarker of the j th arm of the i th study are given by:
where TVB x is the estimated typical baseline FPG and HbA1c. η B and κ are the random effects of inter-study variabilities (ISV) and inter-arm variabilities (IAV) [23] , respectively. ISV and IAV were assumed to be symmetrically distributed as random variables with mean zero and variance ω ISV 2 and ω IAV 2 . IAV was weighted by the inverse of the square root of the number of patients in the study arm (N ij ) normalized to 100 patients. The reason why IAV was included in this analysis was that IAV is purely the product of a small sample size, because in a randomized trial with an infinite sample size, there are no random differences across arms. Disease progression for FPG was assumed to be a proportional increase with a slope parameter (DP FPG ) relative to the baseline. An exponential error model was used to describe ISV on DP FPG . The placebo effect to FPG levels (E placebo ) was described by a constant model. An exponential error model was used to describe ISV on E placebo . The drug effect (E drug ) to FPG levels was as follows:
where E max is the maximum treatment effect ranging between 0 and 1; ED 50 is the dose resulting in 50% of E max .
The model included the individual potency (ED 50 ) of each drug, but assumed the same E max for drugs with the same mechanism of action. The drug effect was assumed to be constant across studies, i.e., ISV on E drug was not estimated. These models indicate that DPP-4i and GLP-1r inhibit FPG production, and SGLT2i stimulates FPG elimination. An additive error model was used to describe residual error variability (RUV). RUV was weighted by the inverse of the square root of the number of patients in the study arm normalized to 100 patients. Ideally for mean data, residual variability needs to be weighted by the precision of the mean (the inverse of squared standard errors). However, since we did not obtain standard errors in many studies, residuals were weighted by the sample size. After establishing the basic models, covariate modelling was conducted. Age, sex, race, BMI and body weight were selected as candidates for the covariate. Covariate selection was conducted based on clinical plausibility and differences in the objective function value (OFV) estimated by NONMEM between hierarchical models. Forward inclusion and backward exclusion were used to develop the covariate model. Significance levels for forward inclusion and backward exclusion were set at 0.01 and 0.001, respectively.
Model validation
During model building, changes in OFV, Akaike information criterion (AIC), relative standard errors and goodness-of-fit (GOF) plots were used for model evaluation. GOF was investigated using plots of the observation vs. population prediction (PRED) and individual predictions (IPRED), conditionalweighted residuals (CWRES) vs. the treatment duration [24] , CWRES vs. PRED, and absolute individual weighted residuals (IWRES) vs. IPRED. In order to assess the robustness of the final PD model, a prediction-corrected visual predictive check (pcVPC) was conducted. An 80% prediction interval (PI) was defined for pcVPC from the 10th and 90th percentiles of simulated dependent data at each time point and was then compared with original data. One thousand simulations were performed for pcVPC. pcVPC was performed with the software package Perl-speaks-NONMEM version 4.8.1.
Simulation
Using the final models, we simulated reductions in FPG and HbA1c 90 days after the initiation of add-on therapy. The dosage was set to the recommended dose of each drug in Japan. Parameter uncertainty, obtained from the variancecovariance matrix of the final model, was implemented in the simulations. The typical time courses of FPG and HbA1c for the three drugs (vildagliptin, exenatide and canagliflozin), which were selected from each drug class, were simulated. Table 1 Study characteristics for each drug 
Results
Data analysis
A total of 2397 publications were found in the initial literature search. After screening and eligibility evaluations, 76 studies (31 585 patients) were eligible for the analysis, including 55 studies on DPP-4i (eight drugs), 10 on GLP-1r (four drugs), and 18 on SGLT2i (four drugs). However, some targeted drugs (e.g., trelagliptin, luseogliflozin and tofogliflozin) were not included in the analysis because trial data were not available. Detailed literature search results are shown in the PRISMA flow diagram ( Figure S1 ), and a study design summary is provided in Supplementary Table S2 . The total numbers of FPG and HbA1c were 873 and 1086, respectively. The medians (ranges) for the baseline values of FPG and HbA1c were 165 mg dl À1 (138-244 mg dl À1 ) and 8.0%
(7.0-9.3%), respectively. The characteristics of each targeted drug are summarized in Table 1 . Figure 1 shows a constructed indirect response model that describes changes in FPG and HbA1c levels over time for all treatments. Figure 1 The final population pharmacodynamic model describing the time course of fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c)DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; K in,FPG , FPG production rate constant; K in,HbA1c , HbA1c production rate constant; K out,FPG , FPG elimination rate constant; K out, HbA1c ; HbA1c elimination rate constant; SGLT2, sodium glucose cotransporter 2 Second-line therapy of metformin in T2DM by MBMA 0.0393/day, respectively. None of the covariates were found to significantly improve the PPD model.
PPD models
Model validation
GOF plots show the high predictive performance of the constructed models, and systematic deviations were not observed ( Figure S2 ). pcVPCs for each drug class are shown in Figure 2 . These models captured most of the observed data, indicating the good predictive performance of the models. These results suggest that the final models adequately describe the time courses for the FPG-and HbA1c-lowering effects of the targeted drugs.
Simulation
Based on the final models, we simulated reductions in FPG and HbA1c 90 days after the initiation of add-on therapy ( Figure 3) . The dosage was set to the recommended dose of each drug in Japan. Parameter uncertainty was implemented in the simulations because some parameters (e.g., ED 50 for Figure 2 Prediction-corrected visual predictive check plots for fasting plasma glucose (FPG) of the placebo (A), dipeptidyl peptidase-4 inhibitors (DPP-4i) (B), glucagon-like peptide-1 receptor agonists (GLP-1r) (C), and sodium glucose cotransporter 2 inhibitors (SGLT2i) (D) as well as haemoglobin A1c (HbA1c) of the placebo (E), DPP-4i (F), GLP-1r (G) and SGLT2i (H). Red solid lines represent the observed median. Blue solid and dashed lines represent the predicted median and 80% prediction intervals, respectively. Open circles represent observed data, and the symbol size is proportional to the number of subjects in each studyQW, once weekly; BID, twice daily omarigliptin and empagliflozin, Table 2 ) were estimated with poor precision. Among these drugs, GLP-1r (exenatide QW, liraglutide and dulaglutide) showed superior FPG-and HbA1c-lowering effects (À22.2, À19.7 and À19.4% for FPG, and À16.8, À14.7 and À14.7% for HbA1c, respectively). FPG-and HbA1c-lowering effects were similar between DPP4i and SGLT2i. Median reductions in FPG were À10.9 to À14.4% for SGLT2i and À9.6 to À12.6% for DPP-4i. Median reductions in HbA1c were À6.9 to À9.2% for SGLT2i and À7.6 to À10.0% for DPP-4i. The typical time courses of FPG and HbA1c of the three drugs, which were selected from each drug class, were simulated and are shown in Figure 4 .
Discussion
The aim of the present study was to quantitate the hypoglycaemic effects of DPP-4i, GLP-1r and SGLT2i as addon treatments to metformin monotherapy in T2DM patients using MBMA. We demonstrated that GLP-1r was associated with greater reductions in FPG and HbA1c than the other treatments tested within the approved dosages in Japan (Figure 3) . The significant superiority of GLP-1r to DPP-4i as add-on therapy to metformin has been suggested in most RCTs. For example, exenatide (2 mg week À1 ) resulted in significantly greater improvements in HbA1c than sitagliptin (100 mg day À1 ) in the DURATION-2 study [29] . Furthermore, the network meta-analysis (NMA) conducted by Zintzaras et al. indicated a higher proportion achieving the HbA1c goal with GLP-1r than other combination therapies with metformin [30] . The DURATION-8 study, which compared the efficacy and safety of exenatide (2 mg week À1 ) vs. dapagliflozin (10 mg day À1 ),
showed that reductions in HbA1c at week 12 were greater in patients given exenatide [31] .
In comparisons between long-and short-acting GLP-1r, treatments with long-acting GLP-1r (i.e., exenatide QW, dulaglutide and liraglutide) have been associated with greater reductions in FPG and HbA1c ( Figure 3) ; long-acting GLP-1r provide relatively stable drug concentration-time profiles in the long term, leading to stable glycaemic control [32] [33] [34] . The NMA conducted by Kayaniyil et al. showed that the administration of exenatide QW led to a slightly higher proportion of patients achieving the glycaemic target than exenatide BID and lixisenatide [35] .
The present study developed a PPD model that combined with the physiological relationship between FPG and HbA1c. During the model building process, we combined the mechanism of action of each drug class into the model: DPP-4i and GLP-1r inhibit FPG production, and SGLT2i stimulates FPG elimination. A large number of physiological models have been developed to describe the relationship between FPG and HbA1c. Our PPD parameters were similar to those Figure 3 Reductions in FPG (A) and HbA1c (B) 90 days after the initiation of add-on therapy. Each square and bar represent the median and 90% confidence interval from model simulation (n = 1000) for each drug. Red, green, and blue squares and bars represent changes from the baseline in FPG for GLP-1r, SGLT2 and DPP-4, respectively. The dosage was set to the recommended dose of each drug in JapanQW, once weekly; BID, twice daily Second-line therapy of metformin in T2DM by MBMA reported previously [21, 22] . The FPG progression rate was estimated to be 2.04%/year and was similar to that reported by Stringer et al. (1.7%/year) [22] . In the present study, disease progression for FPG was assumed to be a proportional increase with DP FPG . Several different disease progression models have been investigated (e.g., log-linear and exponential), but were not found to be superior.
The relationship between FPG and HbA1c was found to be nonlinear and was described by a power function with a different λ for the placebo and each drug class. Our estimated λ was similar to values reported in previous studies (0.74 and 0.71) [20, 21] . The nonlinear relationship between FPG and HbA1c may result from the contribution of postprandial glucose because the value for HbA1c is the result of FPG and postprandial glucose [36] . In addition, previous studies demonstrated that mean plasma glucose (the arithmetic mean of FPG and postprandial glucose) correlated better with HbA1c than FPG alone [37, 38] .
This MBMA has several limitations. For example, covariate information obtained from the literature was limited. Some information, such as the metformin dose and durations of T2DM and metformin monotherapy, was not consistently reported; therefore, we were unable to include these as candidates for the covariate analysis. Since this information may contribute to patient heterogeneity, the results of the covariate analysis need to be interpreted with caution.
In conclusion, this MBMA quantified the hypoglycaemic effects of DPP-4i, GLP-1r and SGLT2i when they were added to metformin monotherapy. The simulations based on PPD models suggested that long-acting GLP-1r (i.e., exenatide QW, liraglutide and dulaglutide) were more effective than other drugs for T2DM patients inadequately controlled with metformin monotherapy.
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